Materiały źródłowe

• #1 Hereditary Hemorrhagic Telangiectasia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1351/

  Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of multiple arteriovenous malformations (AVMs) that lack intervening capillaries and result in direct connections between arteries and veins. […] The diagnosis of HHT is established in a proband with three or more of the following clinical features: Epistaxis, Mucocutaneous telangiectases in characteristic locations, Visceral AVMs, A first-degree relative diagnosed with HHT on the basis of the preceding criteria. […] Annual evaluation by a health care provider familiar with HHT for signs and symptoms of complications; annual hematocrit, hemoglobin, and ferritin; evaluation for pulmonary AVMs every five years with transthoracic contrast echocardiography (TCE) in adults, TCE or chest radiograph with pulse oximetry in children; brain MRI with and without contrast using sequences that detect blood products in infancy and again after puberty for cerebral AVMs; colonoscopy at age 15 years and repeated every three years if no polyps are found, or annually with esophagogastroduodenoscopy if colonic polyps are identified in those with SMAD4-HHT. […] The incidence of HHT in North America is estimated at 1:10,000; however, this is likely an underestimate. […] HHT occurs with wide ethnic and geographic distribution. The condition is especially prevalent in the Netherland Antilles because of a founder effect.

• #2 Hereditary haemorrhagic telangiectasia | Nature Reviews Disease Primers

  https://www.nature.com/articles/s41572-024-00585-z

  Hereditary haemorrhagic telangiectasia (HHT) is a vascular dysplasia inherited as an autosomal dominant trait and caused by loss-of-function pathogenic variants in genes encoding proteins of the BMP signalling pathway. […] In adults, the most frequent HHT manifestations relate to iron deficiency and anaemia owing to recurrent epistaxis (nosebleeds) or bleeding from gastrointestinal telangiectases. […] Management goals encompass control of epistaxis and intestinal bleeding from telangiectases, screening for and treatment of iron deficiency (with or without anaemia) and AVMs, genetic counselling and evaluation of at-risk family members. […] Although HHT is associated with increased morbidity, the appropriate screening and treatment of visceral AVMs, and the effective management of bleeding and anaemia, improves quality of life and overall survival. […] Epidemiology (C.L.S, M.S., R.H., R.S.K. and S.D.-G.);

• #3 Hereditary Hemorrhagic Telangiectasia: Genetics, Pathophysiology, Diagnosis, and Management

  https://www.mdpi.com/2077-0383/11/17/5245

  Hereditary hemorrhagic telangiectasia (HHT), also known as Rendu–Osler–Weber Syndrome, is a rare disease characterized by multisystemic vascular dysplasia. Its prevalence is, according to recent estimates, 1 case per 5000 inhabitants. However, there are geographical areas where frequencies are higher, such as the Dutch Antilles, the island of Funen, Denmark, the French region of Ain, Vermont (USA), Newcastle (United Kingdom), and Las Palmas de Gran Canaria (Spain). […] This disease is caused, in approximately 90% of cases, by a heterozygous mutation of the endoglin gene (ENG) or the activin-like receptor kinase 1, called ALK1 (also known as ACVRL1), characterized by an autosomal dominant inheritance pattern. […] Studies based on the Spanish registry (Registro informatizado de la telangiectasia hemorrágica hereditaria, RiTHHA, in Spanish) showed a different correlation between genotype and phenotypic expressions.

• #4 Hereditary hemorrhagic telangiectasia: MedlinePlus GeneticsLock

  https://medlineplus.gov/genetics/condition/hereditary-hemorrhagic-telangiectasia/

  Hereditary hemorrhagic telangiectasia is a disorder that results in the development of multiple abnormalities in the blood vessels. […] The incidence of hereditary hemorrhagic telangiectasia is difficult to determine because the severity of symptoms can vary widely and some symptoms, such as frequent nosebleeds, are common in the general population. Hereditary hemorrhagic telangiectasia is widely distributed, occurring in many ethnic groups around the world. It is believed to affect between 1 in 5,000 and 1 in 10,000 people. […] This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.

• #5 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia): Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/2048472-overview

  OWRD (ie, HHT) is rare in North America. The reported incidence is 1-2 cases per 100,000 population annually. The overall prevalence is estimated to be approximately 1-2 cases per 10,000 population. However, the prevalence may be underestimated because many cases may be asymptomatic. […] The worldwide prevalence is 1 case per 5000-10,000 population In Europe and Japan, the frequency is estimated to be between 1 in 5000 to 8000 people. […] HHT may occur in children, in whom a tendency to bleed may be the first symptom. However, it is far more common during puberty or adulthood. The syndrome most often manifests by the second or third decade of life, though it may also be clinically silent. Pulmonary AVMs may be congenital and therefore may present within the first year of life. The risk of GI tract bleeding increases in patients older than 50 years. […] HHT occurs with equal frequency and severity in males and females. Although it most commonly occurs in whites, it has a wide geographic distribution and has been described in people of Asian, African, and Arabic descent.

• #6 Hereditary Hemorrhagic Telangiectasia (HHT) | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/141559

  HHT affects 1 in 5,000-8,000 individuals and can affect both genders and people of all races. […] Some studies have noted a higher incidence in women, although this gender difference may be attributed to access to healthcare resources.

• #7 Hereditary Hemorrhagic Telangiectasia (HHT) – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK578186/

  HHT affects 1 in 5,000-8,000 individuals and can affect both genders and people of all races. Some studies have noted a higher incidence in women, although this gender difference may be attributed to access to healthcare resources. […] The classic triad consists of epistaxis, telangiectasias, and positive family history of similarly affected individuals. […] The diagnosis of HHT has relied on Curaao Criteria, which encompasses the classic features of the disease: 1) spontaneous, recurrent epistaxis, 2) positive family history, 3) cutaneous or mucosal telangiectasias, and 4) visceral lesions. A definitive diagnosis is made if patients have 3 of the 4 criteria, and a possible or suspected diagnosis is made if patients meet 2 of the 4 criteria. […] Genetic mutation testing should be done to confirm a diagnosis of HHT, including patients who meet 1-2 of the Curaao criteria or young children with affected parents who are yet to develop the clinical manifestations. […] HHT can affect multiple organ systems, and early recognition and screening for clinical manifestations and prompt interventions can decrease morbidity and mortality.

• #8 Hereditary Hemorrhagic Telangiectasia (HHT)

  https://my.clevelandclinic.org/health/diseases/15618-hereditary-hemorrhagic-telangiectasia-hht

  Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder that affects blood vessel formation. […] HHT can affect men, women and children from all racial and ethnic groups. Its genetic, so it runs in families. The disorder is rare, but its also underdiagnosed, meaning many people have it without knowing. Its estimated to affect 1 in 5,000 people worldwide, but a high percentage arent clinically diagnosed. […] Genetic testing can identify HHT, but most people are diagnosed based on clinical information. […] There is no way to prevent HHT or reduce your risk of getting it. But tell your healthcare provider if your parent, sibling or child has it. That may help you catch it early and prevent complications. […] People with HHT have an almost average life expectancy. But AVMs in the lungs and brain and chronic bleeding are serious and should be treated.

• #9 Hereditary hemorrhagic telangiectasia | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/hereditary-haemorrhagic-telangiectasia?case_id=pulmonary-arteriovenous-malformation

  Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a rare inherited disorder characterized by abnormal blood vessel formation in the skin, mucous membranes, and organs including the lungs, liver, and central nervous system. […] Worldwide prevalence ~1.5 per 100,000. Wide geographic variability with a much higher incidence in certain regions, e.g. 1 in 200 in Dutch Antilles, 1 in 3500 in France.

• #10

  https://haematologica.org/article/view/8582

  Hereditary hemorrhagic telangiectasia affects approximately 1 in 5000 individuals in North America, but the highest prevalence is seen in the Afro-Caribbean regions of the Dutch Antilles and France. There is also variability regarding HHT subtype, with type 1 HHT being found more in North America and Europe and type 2 being more common in the Mediterranean and South America. However, these statistics may underestimate the actual disease prevalence as the diagnosis is often missed and some patients may be asymptomatic. HHT exhibits incomplete penetrance and clinical manifestations can vary between patients, even within families with known mutations. […] Patients may relate a history of epistaxis in childhood, often apparent during adolescence. Mild epistaxis or bleeding tendencies increase with age and telangiectasias may be seen after adolescence, often in adulthood. Clinical signs of bleeding become more apparent in adulthood, often after the age of 40 years. Symptoms from anemia may be an initial complaint at presentation from gastrointestinal bleeding, seen in approximately one-third of patients. Patients with mutations of ACVRL1 may present later in life, while those with MADH4 mutations may present earlier in childhood with juvenile colonic polyps and early onset colorectal cancer (at a mean age of 28 years).

• #10

  https://haematologica.org/article/view/8582

  As a population, patients with HHT probably have a reduced life expectancy, but this is highly dependent on the severity of disease. Patients without internal organ manifestations (such as hepatic, cerebral or pulmonary AVMs) are expected to have a normal or near-normal lifespan, but approximately 10% of patients may die or become debilitated from vascular complications. In a large case-control study, 675 HHT patients were compared with age- and sex-matched healthy controls using a population-based UK primary care database. Patients with HHT were more likely to suffer from cerebral abscess, migraine, ischemic/embolic stroke, heart failure, colon cancer, and the numerous bleeding complications characteristic of the disease. The hazard ratio for death for patients with HHT compared with controls was 2.03 (CI: 1.59-2.60; P0.0001). Life expectancy was seven years shorter in HHT patients in one study, with two mortality peaks, one under 50 years and one between 60-79 years of age. Finally, a population study in Denmark demonstrated mortality rates double that of the general population in those under 60 years of age.

• #11

  https://link.springer.com/article/10.1007/s10792-021-02197-y

  There is wide geographic variability however, the highest prevalence is among the Afro-Caribbean population of the island of Curaao and Bonaire (1 case in 1331 inhabitants) from which derive the Curacao diagnostic criteria. […] HHT type 1 is more frequent in North America and in Northern Europe. HHT type 2 more prevalent in Mediterranean countries such as Italy, France, and Spain. […] The initial diagnosis is frequently made based on recurrent epistaxis, oral lesions discovered during routine dental examination, and ocular signs. […] Formal diagnosis of HHT is made according to the Curaao criteria: telangiectasia on the face, hand and oral cavity, recurrent epistaxis, arterio-venous malformations with visceral involvement, and familial history. […] Increased knowledge of the disease and a multidisciplinary approach can potentially accelerate diagnosis and consequently improve the quality of life of patients.

• #12 Hereditary hemorrhagic telangiectasia – Wikipedia

  https://en.wikipedia.org/wiki/Hereditary_hemorrhagic_telangiectasia

  Population studies from numerous areas in the world have shown that HHT occurs at roughly the same rate in almost all populations: somewhere around 1 in 5000. In some areas, it is much more common; for instance, in the French region of Haut Jura the rate is 1:2351 – twice as common as in other populations. This has been attributed to a founder effect, in which a population descending from a small number of ancestors has a high rate of a particular genetic trait because one of these ancestors harbored this trait. […] The highest rate of HHT is 1:1331, reported in Bonaire and Curaao, two islands in the Caribbean belonging to the Netherlands Antilles. […] Most people with HHT have a normal lifespan. The skin lesions and nosebleeds tend to develop during childhood. AVMs are probably present from birth, but don’t necessarily cause any symptoms. Frequent nosebleeds are the most common symptom and can significantly affect quality of life.

• #13 Hereditary hemorrhagic telangiectasia – wikidoc

  https://www.wikidoc.org/index.php/Hereditary_hemorrhagic_telangiectasia

  HHT occurs mainly in whites (1:5,000), more in certain areas of France, but much less in blacks (1 in million). […] It is found in all continents throughout the world. […] It is also seen with increased frequency in Mormon families from Utah.

• #14

  https://link.springer.com/article/10.1007/s10792-021-02197-y

  Hereditary haemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber syndrome is a rare autosomal dominant disease, characterised by systemic angiodysplasia. […] The disease affects the elastic and muscle layers of the vessel walls with a consequent increased susceptibility to ruptures and bleeding episodes. […] HHT is characterised by multiple arterio-venous malformations (AVMs) where arteries and veins are connected in the absence of capillaries. […] Transmission is autosomal dominant with incomplete expression in some cases, and sporadic mutations are involved in 20% of cases. […] HHT shows age-related penetrance and clinical manifestations develop over time. […] Awareness of HHT and early diagnosis is crucial to avoid the pitfalls of potentially severe complications in routine medical practice.

• #15 Osler-Weber-Rendu Syndrome (HHT/HHT1) | Doctor

  https://patient.info/doctor/osler-weber-rendu-syndrome

  Hereditary haemorrhagic telangiectasia (HHT) is also known as Osler-Weber-Rendu syndrome. The population prevalence is between 1 in 5,000 and 1 in 8,000. There is no difference between sexes. There are some pockets of increased prevalence such as Afro-Caribbean people of Curacao and Bonaire. […] Age-related penetrance is seen in HHT. It does not present at birth but commonly presents with recurrent epistaxis, usually in the teenage years. […] The diagnosis is made if at least three of the following are present: Epistaxes, Telangiectasia, Visceral lesions, Appropriate family history. […] Optimal management is improved with early diagnosis, based on clinical findings.

• #16 International HHT Guidelines

  https://hhtguidelines.org/

  Announcing the Second International HHT Guidelines for the Diagnosis and Management of HHT, published in the Annals of Internal Medicine. […] The HHT Guidelines recommendations should facilitate the implementation of key components of HHT (Hereditary Hemorrhagic Telangiectasia) care into clinical practice. […] Timely diagnosis of HHT allows for the appropriate screening and preventative treatment for the individual with HHT and their family members. […] At least 40% of people with HHT have pulmonary AVMs. They are often unaware until they develop a life-threatening complication. Screening and treatment can prevent life-threatening complications. […] At least 10% of people with HHT have VMs in the brain blood vessels. They are often unaware of these brain VMs until they develop a life-threatening complication.

• #17 Hereditary Hemorrhagic Telangiectasia: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2010/1001/p785.html

  Hereditary hemorrhagic telangiectasia is an uncommon autosomal dominant disease that occurs in approximately one in 5,000 to 8,000 persons. […] Screening and treatment recommendations have been created in an attempt to limit the morbidity and mortality associated with this disease. Patients with confirmed or suspected hereditary hemorrhagic telangiectasia should be screened for brain and lung arteriovenous malformations using magnetic resonance imaging of the brain and contrast echocardiography. […] A better understanding of the many clinical manifestations of HHT, in addition to better screening protocols and diagnostic testing, has helped to determine that the disease is more common than once thought. […] Screening should include contrast echocardiography and MRI of the brain. […] Patients with a negative result on contrast echocardiography should repeat the test every three to five years to monitor for the development of new pulmonary AVMs.

• #17 Hereditary Hemorrhagic Telangiectasia: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2010/1001/p785.html

  Adults with possible or confirmed HHT should receive an MRI to screen for cerebrovascular AVMs using a protocol with and without contrast media administration and using sequences that detect blood products to maximize sensitivity. […] Screening for GI and liver involvement is recommended only for patients who demonstrate possible symptoms such as GI bleeding, anemia of unknown etiology, or hepatic or cardiac failure.

• #18 Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence

  https://www.mdpi.com/2077-0383/9/11/3581

  Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant disease, with prevalence rates between 1:5000 and 1:8000 and with approximately 85,000 affected citizens in Europe. […] According to the current International HHT Guidelines screening and, if indicated, treatment of HHT-related organ involvement is strongly recommended in a center with HHT expertise. […] We found that the life expectancy of patients with HHT who have been systematically screened for HHT-related organ involvement, treated if needed and followed in a center with HHT expertise did not differ from the life expectancy of the non-HHT control group. […] These findings demonstrate the importance of systematic screening of HHT patients and treatment of PAVMs and other HHT-related organ involvement.

• #19 Hereditary Hemorrhagic Telangiectasia: Genetics, Pathophysiology, Diagnosis, and Management

  https://www.mdpi.com/2077-0383/11/17/5245

  The recommended initial test is transthoracic contrast echocardiography (TTCE) with bubbles. Its sensitivity is between 93 and 100%, and since it is noninvasive, it is still the first step in the approach to these patients. […] In patients with a negative first study or grade 1, it is recommended to follow a conservative strategy of repeating TTCE every 5 years. […] In cases obtaining a grade 2 or higher, a CT scan should be performed. […] For cerebral AVMs, MRI is recommended in children and some reviews suggest this at the time of diagnosis. […] When encountering a patient with suspected HHT in the consultation room, screening should be initiated with clinical history, physical examination, and laboratory tests.

• #20 Hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: clinical aspects – Meier – Cardiovascular Diagnosis and Therapy

  https://cdt.amegroups.org/article/view/18281/html

  Effective screening is necessary to identify which HHT patients have PAVMs so that their dire clinical consequences can be avoided. Transthoracic contrast echocardiography (TTCE) is the preferred method for PAVM screening because of its high sensitivity and excellent negative predictive value. […] PAVM screening is recommended for all patients at the initial HHT evaluation. If negative, repeat screening is recommended after puberty, within 5 years of planned pregnancy, after pregnancy, and otherwise every 5 to 10 years. […] The goals of PAVM management are to minimize embolic complications, prevent and treat hemorrhage from PAVM rupture, and improve functional capacity by reducing shunt-related hypoxemia.

• #21 HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

  https://www.metropolitan-hospital.gr/en/about-us/63-medical-services/general-services/653-hereditary-hemorrhagic-telangiectasia-hht

  Hereditary Hemorrhagic Telangiectasia (HHT) is a multisystemic disease that affect a number of organs. […] The prevalence of HHT is estimated at 1 in 5,000 to 1 in 10,000 people, depending on geographic region. […] HHT is inherited in an autosomal dominant manner. […] Clinical diagnosis of HHT is based on the Curacao criteria, which were published in 2000. […] HHT patients must be followed up by a specialized center for life. […] Upon diagnosis of HHT, first-degree relatives must undergo genetic testing. Particular emphasis is placed on testing relatives for PAVMs due to high familial incidence (35%).

• #22 Hereditary haemorrhagic telangiectasia: diagnosis, screening and management | Medicine Today

  https://medicinetoday.com.au/mt/2023/may/regular-series/hereditary-haemorrhagic-telangiectasia-diagnosis-screening-and-management

  Hereditary haemorrhagic telangiectasia (HHT), also known as OslerWeberRendu syndrome, is an autosomal dominant genetic disorder characterised by the presence of dilated or broken blood vessels near the surface of the skin or mucous membranes (telangiectasias) and arteriovenous malformations (AVMs). The estimated prevalence is one in 5000 individuals; however, this is probably an underestimation. Patients with HHT may have AVMs in various visceral organs and experience serious complications because of bleeding or shunting of blood through abnormal vessels. The prognosis varies, and mortality rates may be as high as double those in the general population for patients younger than 60 years of age, with worse survival in patients with internal organ manifestations. […] HHT is underdiagnosed, and there is often a delay in diagnosis. Thus, it is important for primary care physicians to recognise the presentation of HHT, as prompt diagnosis allows for appropriate screening and preventative treatment in both patients and affected family members. Early screening by GPs and referrals to specialists may reduce morbidity and mortality associated with pulmonary or central nervous system (CNS) AVMs, as patients with these complications are assessed and pre-emptively treated at HHT centres. Management is best delivered in conjunction with a multidisciplinary team. This review outlines the diagnosis of HHT and, screening and treatment of HHT-related complications. […] One of the most important aspects of HHT care is to screen for potential end-organ involvement. The modality and frequency of screening are based on expert opinion, with recommended screening investigations outlined in the text.

• #23 Orphanet: Hereditary hemorrhagic telangiectasia

  https://www.orpha.net/en/disease/detail/774

  An inherited disorder of angiogenesis characterized by mucocutaneous telangiectases and visceral arteriovenous malformations. […] The prevalence is approximately 1/6,000. […] Disease management includes prevention and treatment of epistaxis and anaemia, screening for AVMs, and guidance regarding pregnancy-related issues. […] Life expectancy is reduced in unscreened patients. In patients assessed and treated for pulmonary AVMs in an HHT Center, life expectancy is comparable to the general population.

• #24 Hereditary Haemorrhagic Telangiectasia in Denmark. Surveillance – manifestations of the disease

  https://open.rsyd.dk/OpenProjects/openProject.jsp?openNo=128&lang=en

  Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu disease, is an autosomal dominantly inherited disease, with high penetrance, extremely variable age-dependent expression and very heterogeneous phenotypic presentations. Around 800 Danes are affected. HHT is characterized by the presence of multiple telangiectatic lesions in the mucosa and the skin and development of arteriovenous lesions. The various sorts of vascular malformations may cause life-threatening symptoms, which may be difficult to treat. Evaluation of the patients are centralised at the HHT-center at Odense University Hospital (OUH). […] As HHT is a rare disease with very variable manifestations, there is a great risk of selection bias, as only the most severely affected patients are referred for treatment on a regular basis. The mildly affected cases are often only seen at the HHT center once, at the time of diagnosis.

• #25 Quantifying the burden of hereditary hemorrhagic telangiectasia on quality of life and psychological health: a cross-sectional study | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03620-8

  Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant multisystem vascular disorder, characterized by the presence of arteriovenous malformations (AVMs) and telangiectasias, especially affecting the skin, nose, lungs, liver, gastrointestinal tract, and central nervous system. […] Health-related QoL (HRQoL) is an essential indicator to assess the broader impact of chronic conditions like HHT, beyond the immediate physical symptoms, to quantify the influence of a medical condition, and to evaluate the effectiveness of therapeutic interventions. […] Despite the known extensive burden of HHT, research into its psychosocial outcomes remains sparse. […] The complexity of HHT symptoms and the way they are managed can profoundly affect individuals mental health, social interactions, ability to function, and overall QoL, suggesting a substantial but underexplored area of influence on HRQoL.

• #25 Quantifying the burden of hereditary hemorrhagic telangiectasia on quality of life and psychological health: a cross-sectional study | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03620-8

  This study addresses a gap in the literature by examining how HHT-related manifestations affect patients psychosocial health and QOL. […] Our findings emphasize the multifaceted impact of HHT on patients lives and how several HHT-related manifestations might be associated with adverse psychological outcomes and low QoL. […] Acknowledging the full scope of HHTs negative effects is essential for a more nuanced understanding and management of this condition, improving patient care and effective target interventions.

• #26 Hereditary Hemorrhagic Telangiectasia Disease (HHT) Market – Global Market – Industry Trends and Forecast to 2028 | Data Bridge Market Research

  https://www.databridgemarketresearch.com/reports/global-hereditary-hemorrhagic-telangiectasia-disease-hht-market?srsltid=AfmBOopzhRnv0SaRThUQp_ckv265GevC4Mc399meoXTiVegdqjLnFAHd

  Hereditary hemorrhagic telangiectasia disease (HHT) market is expected to gain market growth at a potential rate of 4.00% in the forecast period of 2021 to 2028. […] Rise in the prevalence of the disease (HHT) acts as the vital factor escalating the hereditary hemorrhagic telangiectasia disease (HHT) market growth. […] Rise in the government awareness programs about the disease will uplift the market growth, also rise in the population, rise in the healthcare affordability in the US and rise in the knowledge and awareness amongst the people are some of the crucial factors among others driving the hereditary hemorrhagic telangiectasia disease (HHT) market growth. […] The country section of the hereditary hemorrhagic telangiectasia disease (HHT) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market.

• #26 Hereditary Hemorrhagic Telangiectasia Disease (HHT) Market – Global Market – Industry Trends and Forecast to 2028 | Data Bridge Market Research

  https://www.databridgemarketresearch.com/reports/global-hereditary-hemorrhagic-telangiectasia-disease-hht-market?srsltid=AfmBOopzhRnv0SaRThUQp_ckv265GevC4Mc399meoXTiVegdqjLnFAHd

  Data points such as new sales, replacement sales, country demographics, disease (HHT) epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. […] Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report.

Zobacz więcej